Search results
Found 30 matches for
The University of Oxford and Sound Pharmaceuticals completed this new Phase 2a study testing SPI-1005, an investigational drug that contains ebselen, as a new treatment for bipolar disorder.
Young people's development in adversity and delivering effective interventions
Anxiety Brain Depression HIV Neuroimaging PTSD Parenting Refugees and asylum seekers Treatment trials
The research is predominantly concerned with the development of children and adolescents in the face of adversity. There are two objectives. The first has been to elucidate the environmental mechanisms underlying development in adversity. The second has been to use this understanding to develop interventions to enhance children’s and young people's development and support their families.